Skip Navigation
Menu
Ideas and Opinions |16 January 2018

Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders

M. Eugenia Socías, MD, MSc; Evan Wood, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 26 December 2017.
  • From University of British Columbia and British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.

    Acknowledgment: The authors thank Jennifer Navin for her administrative assistance and Leo Beletsky for his legal advice.

    Financial Support: Dr. Wood is a Tier 1 Canada Research Chairholder. Dr. Socías is supported by postdoctoral fellowship awards from the Michael Smith Foundation for Health Research and the Canadian Institute for Health Research.

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2373.

    Requests for Single Reprints: Evan Wood, MD, PhD, British Columbia Centre on Substance Use, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada; e-mail, bccsu-ew@cfenet.ubc.ca.

    Current Author Addresses: Drs. Socías and Wood: British Columbia Centre on Substance Use, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.

    Author Contributions: Conception and design: M.E. Socías, E. Wood.

    Analysis and interpretation of the data: M.E. Socías, E. Wood.

    Drafting of the article: M.E. Socías.

    Critical revision for important intellectual content: M.E. Socías, E. Wood.

    Final approval of the article: M.E. Socías, E. Wood.

×
FULL TEXT
North America is in the midst of an unprecedented public health crisis of opioid-related morbidity and mortality, fueled by the increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogues (1). It is estimated that more than 2.5 million Americans have an opioid use disorder (OUD) and that more than 33 000 died from an opioid-related overdose in 2015—quadrupling the rates from 1999 (1). The scale and trajectory of the opioid overdose epidemic in North America underscore the need for an urgent scale-up and evaluation of science-driven solutions (2). Lessons drawn from the response to the HIV epidemic and, more recently, the Ebola virus outbreak show that prompt identification of and access to effective interventions are cornerstone elements in responding to any public health emergency (3, 4).
Fortunately, evidence-based treatments for OUD exist. However, despite the proven individual- and community-level benefits of opioid agonist therapy (OAT)—with buprenorphine or methadone (5, 6)—several health system and regulatory barriers to this treatment persist throughout North America, significantly undermining the population-level effect of these programs (6). In addition, buprenorphine and methadone may not be effective for all patients, with some studies indicating that fewer than 50% of persons who begin OAT with these medications are still receiving treatment at 6 months (7). The barriers to successful uptake and long-term engagement with OAT in the United States have resulted in a large unmet treatment need, leaving...
FULL TEXT
PDF
Not Available
Citations
Citation

Socías ME, Wood E. Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders. Ann Intern Med. 2018;168:141–142. [Epub ahead of print 26 December 2017]. doi: https://doi.org/10.7326/M17-2373

Download citation file:

© 2020

×
Permissions

Published: Ann Intern Med. 2018;168(2):141-142.

DOI: 10.7326/M17-2373

Published at www.annals.org on 26 December 2017

©
2017 American College of Physicians
3 Citations

Related Articles
Annals for Educators - 6 November 2018
Annals of Internal Medicine; 169 (9): ED9
Time to Change the Way We Approach Opioid Use Disorder: A Challenge to the Status Quo
Annals of Internal Medicine; 169 (9): 652-653
When Centers for Medicare & Medicaid Services Treats Throat Cancer Like Pharyngitis
Annals of Internal Medicine; 169 (8): 573-574
Much Choice, Much Confusion: Treating Basal Cell Carcinoma
Annals of Internal Medicine; 169 (7): 500-501
View MoreView Less

Journal Club
Guideline: In adults with opioid use disorders, a stepped treatment approach is recommended
Annals of Internal Medicine; 168 (12): JC62
Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS
Annals of Internal Medicine; 167 (12): JC69
Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non–insulin-treated type 2 diabetes
Annals of Internal Medicine; 167 (8): JC46
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
View MoreView Less

Related Point of Care
Palliative Care
Annals of Internal Medicine; 168 (5): ITC33-ITC48
Clostridioides difficile Infection
Annals of Internal Medicine; 169 (7): ITC49-ITC64
Systemic Lupus Erythematosus
Annals of Internal Medicine; 159 (7): ITC4-1
Polymyalgia Rheumatica
Annals of Internal Medicine; 166 (9): ITC65-ITC80
View MoreView Less

Related Topics
Tobacco, Alcohol, and Other Substance Abuse

Tobacco, Alcohol, and Other Substance Abuse.

PubMed Articles
Associations between Neighborhood-Level Factors and Opioid-Related Mortality: A Multilevel Analysis using Death Certificate Data.
Addiction 2020.
The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy.
Gynecol Oncol 2020.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×